Source: US News & World Report
“A new study suggests GLP-1 medications may slow the spread of certain obesity-related cancers. … Researchers analyzed health data from more than 12,000 people who had one of seven types of cancer at stage 1, 2 or 3. They compared patients who started taking GLP-1 drugs after their diagnosis with similar patients taking another class of diabetes drugs called gliptins. ‘Our study found that use of GLP-1 drugs, compared to DPP-4 inhibitors and other antidiabetic drugs, was associated with a meaningful reduction in cancer progression across four solid tumor types,’ said co-author Dr. Mark David Orland of the Taussig Cancer Institute at the Cleveland Clinic. The strongest results were seen in lung, breast, colon and liver cancer, where patients taking GLP-1 medications were found to be 38% to 50% less likely to progress to stage 4 or metastatic cancer.” (05/27/26)